Please login to the form below
European Society of Cardiology
This page shows the latest European Society of Cardiology news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s heart failure drug Farxiga scores FDA priority review
broad diabetes patient population, most of whom had no cardiovascular disease at enrolment, compared with placebo. ... AstraZeneca’s HFrEF trial of Farxiga – named DAPA-HF – was hailed as a ‘landmark trial’ when it was presented at last
Latest news
-
AZ’s Farxiga gets heart failure prevention okay from FDA
attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ. ... The HFrEF trial, called DAPA-HF, was presented at this year’s European Society of Cardiology (ESC) congress in Paris to some fanfare, showing that
-
TMC preps filings for inclisiran after final phase 3 trials hit the mark
burden. ORION-10 involved patients with atherosclerotic cardiovascular disease (ASCVD), and the results back up the earlier ORION-11 data in the same patient population which was presented at the European ... Society of Cardiology (ESC) congress
-
FDA fast-tracks AstraZeneca’s Farxiga in heart failure
Earlier this month, AZ revealed the results of the DAPA-HF trial of its diabetes therapy Farxiga, to an eager crowd at the European Society of Cardiology. ... This hard-to-treat form of the disease currently has no approved drug therapies.
-
AZ’s Farxiga heart failure results wow the ESC
Lead investigator John McMurray of the University of Glasgow presented the results at the European Society of Cardiology (ESC) congress in Paris over the weekend to an enthusiastic audience. ... non-diabetic population and make it an option for the
-
TMC rockets on data for twice-yearly cholesterol drug inclisiran
The results will be presented at the European Society of Cardiology meeting in Paris next week. ... control the LDL-cholesterol levels despite maximum doses of statin drugs, with or without Merck &Co’s add-on therapy Zetia (ezetimibe).
More from news
Approximately 2 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
Is it possible to change behaviour virtually?
One of my colleagues, Emma, has also incorporated virtual technology into a medical education programme. ... What value did the virtual mannequin add? . It was the first time ever a virtual mannequin had been used at the European Society of Cardiology
-
Helping European cardiologists keep up to date
But when asked about their propensity to take part in programmes in relation to: (1) the sponsoring organisation (independent bodies such as the European Society of Cardiology or an unrestricted grant ... Figure 4: EU5 average of preferences of online
-
Change drivers: multi-stakeholder education and collaboration
Professor John Camm, Chair of the European Society of Cardiology Committee for Guidelines on the Management of Atrial Fibrillation told me recently: “Well-meaning rewording of key messages to 'suit' different ... It resulted in improved cholesterol
-
Closing the treatment gap
Timescale:March 2009 to August 2009. The annual European Society of Cardiology Congress is the largest global cardiology meeting, attracting thousands of delegates and hundreds of journalists; the competition between pharmaceutical ... Merck, with a
-
A very favourable verdict
Timescale:July 2009 to December 2009. Guest delegates of DAIICHI SANKYO UK at the European Society of Cardiology Congress were subpoenaed to appear on a jury at The Formulary Court of ... meetings and will also roll out via a series of regional GP
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Conference research case study
Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. ... meant to our clients key customers and the overall impact of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
